SEC Form 4 · accession 0000899243-18-006561
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Bjerkholt
Officer — Chief Financial Officer
Period of report
Mar 4, 2018
Accepted (ET)
Mar 6, 2018 · 8:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1 | Mar 4, 2018 | A | 9,375 | $0.00 | A | 17,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $34.07 | Mar 4, 2018 | A | 56,250 | A | — | Mar 4, 2028 | Common Stock | 56,250 | 56,250 | D |
Explanation of responses
- F1These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
- F2The shares subject to the option will vest and become exercisable as to one-forty-eighth (1/48th) of the total number of shares subject to the option in successive, equal monthly installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.